The probability of developing ocular EIMs was comparable across treatment classes among patients with HLA-B27-associated diseases.

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering ...

Yuflyma (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent ...

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...

Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children, affecting thousands of young patients across the United States. For some, it comes with a hidden and dangerous ...